SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 8.8% – Still a Buy?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) shares rose 8.8% during trading on Friday . The company traded as high as $8.09 and last traded at $8.2290. Approximately 2,532,904 shares were traded during mid-day trading, a decline of 68% from the average daily volume of 7,875,479 shares. The stock had previously closed at $7.56.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. Maxim Group boosted their price objective on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, March 12th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, SELLAS Life Sciences Group presently has a consensus rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Stock Performance

The stock has a market cap of $1.49 billion, a P/E ratio of -35.07 and a beta of 2.24. The stock’s fifty day simple moving average is $5.23 and its 200-day simple moving average is $3.91.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Larson Financial Group LLC acquired a new stake in shares of SELLAS Life Sciences Group during the fourth quarter worth $26,000. California State Teachers Retirement System increased its position in shares of SELLAS Life Sciences Group by 22.4% during the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after buying an additional 1,709 shares during the period. Beacon Pointe Advisors LLC acquired a new stake in shares of SELLAS Life Sciences Group during the fourth quarter worth $38,000. Concurrent Investment Advisors LLC acquired a new stake in shares of SELLAS Life Sciences Group during the fourth quarter worth $38,000. Finally, Money Concepts Capital Corp acquired a new stake in shares of SELLAS Life Sciences Group during the fourth quarter worth $40,000. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.